NCT07513129 2026-04-13A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And LymphomasM.D. Anderson Cancer CenterPhase 1 Not yet recruiting18 enrolled
NCT05289687 2026-04-03Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLEastern Cooperative Oncology GroupPhase 2 Recruiting20 enrolled